KaliVir Immunotherapeutics Raises $14 Million
KaliVir Immunotherapeutics, a biotechnology company based in Pittsburgh, Pennsylvania, has successfully raised $14 million in a Series A Extension funding round. The round was led by Company K Partners, with additional participation from SV Investment and Flexus Partners.
Company Overview
KaliVir Immunotherapeutics specializes in developing oncolytic virus therapies aimed at treating various types of cancer. These therapies are designed to selectively infect and kill cancer cells, while also stimulating an immune response against tumors.
Leadership and Vision
Helena Chaye, the Chief Executive Officer of KaliVir Immunotherapeutics, is at the helm of the company. Her leadership focuses on advancing the company's innovative therapies to address unmet needs in cancer treatment.
Strategic Use of Funds
While specific uses of the newly acquired funds were not detailed, it is likely that the investment will support further research and development of their oncolytic virus platform, as well as potential expansion of their clinical trials.
Investor Participation
The funding round was prominently led by Company K Partners, with SV Investment and Flexus Partners also contributing. This influx of capital from seasoned investors demonstrates confidence in KaliVir's approach to cancer treatment and its potential impact on the market.
This Series A Extension represents a significant milestone for KaliVir Immunotherapeutics as it continues to develop its pipeline of cancer therapies.